Covid-19 outcome in patients with Connective Tissue Disease with or without Interstitial Lung Disease.

COVID AFFECTS CELLS WITH ACE2  RECEPTOR. THERE IS REDUCED ANGIOTENSIN 2  MRNA AND ITS ACTIVITY IN LUNG TISSUE OF IDIOPATHIC PULMONARY FIBROSIS AND BLEOMYCIN INDUCED LUNG FIBROSIS.WE  ASSUME REDUCED COVID INFECTION DUE TO THIS. CTD MAY CAUSE INTERSTITIAL FIBROSIS AND SO DOES COVID, SO THERE MAY BE MORE LUNG DAMAGE. TREATMENT OF CONNECTIVE TISSUE DISEASE INVOLVES ANTI-INFLAMMATORY DRUGS WHICH MAY BE PROTECTIVE FOR COVID 19 INFECTION. SO THE OUTCOME NEEDS TO BE EVALUATED AND STUDIED.